hero section gradient
16 handpicked stocks

Blockbuster Revival: Beyond the Headlines

This carefully selected collection of stocks represents companies set to benefit from cinema's comeback. Handpicked by our investment team, these assets span the entire entertainment ecosystem from theater chains to film studios and the technology that makes big-screen experiences special.

Author avatar

Han Tan | Market Analyst

Published on July 14

Your Basket's Financial Footprint

Market capitalisation breakdown for the basket 'Blockbuster Revival: Beyond the Headlines'.

Key Takeaways for Investors:
  • Large-cap dominance generally implies lower volatility and broader-market-like performance, reducing tail-risk compared with small-cap baskets.
  • Use as a core, long-term holding rather than a short-term speculative trade.
  • Expect steady, long-term appreciation rather than explosive short-term gains; growth tends to be gradual.
Total Market Cap
  • AMC: $1.48B

  • CNK: $3.14B

  • IMAX: $1.72B

  • Other

About This Group of Stocks

1

Our Expert Thinking

A major analyst upgrade for AMC has signaled renewed confidence in the entire cinema industry. We believe this reflects a turning point where premium content and strategic pricing can drive a theatrical recovery, even as streaming services continue to grow.

2

What You Need to Know

This collection represents the full cinematic value chain, including theater operators, film studios producing blockbuster content, and specialized technology companies. It's a thematic play on the recovery of consumer spending on out-of-home entertainment experiences.

3

Why These Stocks

We've selected companies positioned across the entire movie ecosystem. From the theaters showing films to the studios making them, and even the brands supplying concessions, these stocks provide diversified exposure to cinema's potential comeback.

Why You'll Want to Watch These Stocks

🎬

The Big Screen Comeback

Analysts are signaling a resurgence in theater attendance as studios roll out blockbuster releases. This rising tide could lift multiple companies across the entertainment ecosystem.

🍿

Beyond Just Movies

This collection captures the entire cinema experience economy, from the theaters themselves to the food, drinks, and technology that make movie magic happen.

💰

When Crowds Return, Profits Follow

As audiences flock back to theaters, companies in this basket stand to benefit from increased ticket sales, concessions revenue, and advertising opportunities that had diminished during slow periods.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Global Infrastructure Partners: UAE Exposure Risks

Global Infrastructure Partners: UAE Exposure Risks

The UAE's strategic push for economic diversification and smart city development is creating significant demand for advanced construction and infrastructure solutions. This basket provides exposure to a selection of US and EU-listed companies that supply essential materials, technology, and engineering services to the region's projects.

UAE Infrastructure Global Suppliers Breakdown

UAE Infrastructure Global Suppliers Breakdown

As the UAE continues its ambitious economic diversification, demand for world-class infrastructure creates opportunities for the companies that build it. This basket offers exposure to US and EU-listed industrial, materials, and technology firms that are integral to developing these large-scale projects.

Antiviral M&A Wave: Biotech Opportunities in 2025

Antiviral M&A Wave: Biotech Opportunities in 2025

Merck's $9.2 billion acquisition of Cidara Therapeutics strengthens its antiviral pipeline as a key patent nears expiry. This major deal signals a growing trend of pharmaceutical giants buying smaller biotechs, creating potential opportunities among companies with promising infectious disease therapies.

Frequently Asked Questions